Hematopoiesis News Volume 3.25 | Jun 26 2012

LABORATORY RESEARCH

Overexpression of Interleukin 1 Receptor Accessory Protein in Stem and Progenitor Cells and Outcome Correlation in AML and MDS
Researchers identified genes dysregulated in stem and progenitor cells in high-risk acute myeloid leukemia (AML), and suggested that interleukin-1 receptor accessory protein may be a promising therapeutic and prognostic target in AML and high-risk myelodysplastic syndrome (MDS). [Blood] Abstract

SOCS2 Is Dispensable for BCR/ABL1-Induced Chronic Myeloid Leukemia-Like Disease and for Normal Hematopoietic Stem Cell Function
Scientists demonstrated that although suppressor of cytokine signaling 2 (Socs2) was found to be preferentially expressed in long term hematopoietic stem cells (HSCs), Socs2-deficient HSCs were indistinguishable from wild type HSCs when challenged in competitive bone marrow transplantation experiments. [Leukemia] Abstract

Focal Adhesion Kinase Splice Variants Maintain Primitive Acute Myeloid Leukemia Cells through Altered Wnt Signaling
Targeting focal adhesion kinase (FAK) or ß-catenin efficiently eradicates primitive leukemic cells in vitro suggesting FAK could be a useful therapeutic target for improved treatment of poor prognosis acute myeloid leukemia cases. [Stem Cells] Abstract

Latent HIV-1 Infection Occurs in Multiple Subsets of Hematopoietic Progenitor Cells and Is Reversed by NF-κB Activation
Investigators illuminated the mechanisms through which latent infection can be established in hematopoietic progenitor cells (HPCs) and suggested common pathways through which latent virus could be reactivated in both HPCs and resting memory T cells to eliminate latent reservoirs of HIV-1. [J Virol] Abstract

Differential Control of Hypoxia-Inducible Factor 1 Activity during Pro-Inflammatory Reactions of Human Hematopoietic Cells of Myeloid Lineage
Investigators report that mammalian target of rapamycin (mTOR) kinase is crucially involved in hypoxia-inducible factor 1α (HIF-1α) accumulation/HIF-1 activation in human THP-1 myeloid monocytes, LAD2 mast cells and primary basophils in a variety of different settings. [Int J Biochem Cell Biol] Abstract

Acute Inducible Ablation of GRP78 Reveals Its Role in Hematopoietic Stem Cell Survival, Lymphogenesis and Regulation of Stress Signaling
Researchers demonstrated that GRP78 plays a pleiotropic role in bone marrow cells and contributes to hematopoietic stem cell survival and the maintenance of the lymphoid lineage. [PLoS One] Full Article

Distinctive Contact between CD34+ Hematopoietic Progenitors and CXCL12+ CD271+ Mesenchymal Stromal Cells in Benign and Myelodysplastic Bone Marrow
Scientists analyzed putative mesenchymal stromal cell markers and their relationship to CD34+ hematopoietic stem/progenitor cells within intact human bone marrow in paraffin-embedded bone marrow core biopsies of benign, myelodysplastic syndrome and leukemic marrows using tissue microarrays to facilitate scanning, image analysis and quantitation. [Lab Invest] Abstract

The Sorafenib Plus Nutlin-3 Combination Promotes Synergistic Cytotoxicity in Acute Myeloid Leukemic Cells Irrespectively of the FLT3 and p53 Status
Researchers investigated the effect of Sorafenib plus Nutlin-3 combination in acute myeloid leukemia. [Haematologica] Abstract | Full Article

CLINICAL RESEARCH

T Cell Suicide Gene Therapy Prompts Thymic Renewal in Adults after Hematopoietic Stem Cell Transplantation
In the TK007 clinical trial 22 adults with hematologic malignancies experienced a rapid and sustained immune recovery after T cell-depleted hematopoietic stem cell transplantation and serial infusions of purified donor T cells expressing the herpes simplex virus thymidine kinase suicide gene. [Blood] Abstract

Thalidomide Plus Dexamethasone as a Maintenance Therapy after Autologous Hematopoietic Stem Cell Transplantation Improves Progression-Free Survival in Multiple Myeloma
Researchers assessed the impact of thalidomide in maintenance after stem cell transplantation in untreated patients with multiple myeloma. [Am J Hematol] Abstract

Prognostic Factors Affecting Outcome after Allogeneic Transplantation for Hematological Malignancies from Unrelated Donors: Results from a Randomized Trial
This randomized, multi-center, open-label, phase III trial compared standard graft-versus-host-disease prophylaxis with and without pre-transplant ATG-Fresenius in 201 adult patients receiving myeloablative conditioning prior to hematopoietic stem-cell transplantation from HLA-A, -B antigen, -DRB1, -DQB1 allele matched unrelated donors. [Biol Blood Marrow Transplant] Abstract

Rensselaer and New York State Launch New Stem Cell Research Center
Ground-breaking research to advance the application of stem cells to address critical injuries and diseases will be taking place at Rensselaer Polytechnic Institute, in a new center funded by New York state. [Rensselaer Polytechnic Institute] Press Release

New Scottish-Californian Stem Cell Research Announced
Scientists from Heriot-Watt together with their counterparts in St Andrews and Stanford universities are to work together on new medical research that could lead to major breakthroughs for people living with life-threatening conditions. The Heriot-Watt and St Andrews teams will work with research groups at Stanford to examine how stem cells grow and divide and how they change shape to form different types of tissue. [Heriot-Watt University] Press Release

Rienso^® (Ferumoxytol) Receives European Marketing Authorization for the Treatment of Iron Deficiency Anemia in Adult Chronic Kidney Disease Patients
Takeda Pharmaceutical Company Limited and AMAG Pharmaceuticals, Inc. announced the granting of marketing authorization by the European Commission for ferumoxytol, a new intravenous iron therapy to treat iron deficiency anemia in adult patients with chronic kidney disease. [Takeda Pharmaceutical Company Limited] Press Release

U.K. Panel Backs Open Access for All Publicly Funded Research Papers
A long-awaited government report in the United Kingdom says open access journals should be “the main vehicle for the publication of research.” But it warns that such a move would cost the United Kingdom more than $80 million per year in publication charges and other costs. [The Working Group on Expanding Access to Published Research Findings, United Kingdom] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)
 
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 7th Fraunhofer Life Science Symposium Leipzig 2012
November 29-30, 2012
Leipzig, Germany

NEW Keystone Symposia on Molecular and Cellular Biology: Stem Cell Regulation in Homeostasis and Disease
February 24-March 1, 2013
Banff, Canada
  
Visit our events page to see a complete list of events in the hematopoietic community.

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

PhD Position – Construction of a Biomimetic, Hematopoietic Stem Cell Niche (Karlsruhe Institute of Technology – Helmholtz Association)

Postdoctoral Position – Hematopoietic Stem Cell Biology and Immunology (University of California, San Francisco)

Postdoctoral Position – Hematopoietic Lineage Commitment and Leukemia Development (University of Oxford – Weatherall Institute of Molecular Medicine)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.